Symptomatic and neuroprotective properties of the aliphatic propargylamines

Mechanisms of Ageing and Development

Volumn 111, Issue 2-3, 1999, Pages 201-209

  Boulton, Alan A ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Aliphatic propargylamines; Antiapoptotre drugs; Apoptosis; MAO B; Neurodegenerative disorders; R 2 heptyl N methylpropargylamine (R 2HMP)

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; COPPER ZINC SUPEROXIDE DISMUTASE; DRUG ANALOG; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MONOAMINE OXIDASE INHIBITOR; N METHYL N PROPARGYL 10 AMINOMETHYL DIBENZO[B,F]OXEPIN; N METHYLPROPARGYLAMINE; SELEGILINE; UNCLASSIFIED DRUG;

APOPTOSIS; CONFERENCE PAPER; DEGENERATIVE DISEASE; GENE EXPRESSION; HUMAN; NEUROPROTECTION; PRIORITY JOURNAL;

ALKYNES; ANIMALS; APOPTOSIS; HUMANS; MONOAMINE OXIDASE INHIBITORS; NEURODEGENERATIVE DISEASES;

EID: 0032721502     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0047-6374(99)00073-1     Document Type: Conference Paper

References (37)

1. Berry M.D. R-2HMP. an orally active agent combining independent anti-apoptotic and MAO-B inhibitory activities.@ CNS Drug Rev. 5:1999;105-124.
2. Berry, M.D., Zhang, D., Paterson, I.A., Boulton, A.A., 1998. R-2HMP, an antiapoptotic drug, prevents Ara-C-induced apoptosis in cultured cerebellar granule cells through an interaction with glyceraldehyde-3-phosphate dehydrogenase. ACNP meeting, Puerto Rico, December 1998, PO 105, 145.
3. Boulton A.A., Davis B.A., Durden D.A., Dyck L.E., Juorio A.V., Li X.-M., Paterson I.A., Yu P.H. Aliphatic propargylamines: new antiapoptotic drugs. Drug Dev. Res. 42:1997;150-156.
4. Boulton A.A. From bench to clinic: reflections on the development of some anti-apoptotic drugs. Can. J. Cont. Med. Educ. 11(3):1998;195-202.
5. Boulton A.A., Eisenhofer G. Catecholamine metabolism: from molecular understanding to clinical diagnosis and treatment. Adv. Pharmacol. 42:1998;273-292.
6. Boulton A.A., Yu P.H., Davis B.A., Paterson I.A., Li X.-M., Juorio A.V., Durden D.A., Dyck L.E. Aliphatic N-methylpropargylamines: monoamine oxidase B inhibitors and antiapoptotic drugs. Adv. Pharmacol. 42:1998;308-311.
7. Burke J.R., Enghild J.J., Martin M.E., Jon Y.-S., Myers R.M., Roses A.D., Vance J.M., Strittmatter W.J. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat. Med. 2:1996;347-350.
8. Calne D.B., Langston J.W. Aetiology of Parkinson's Disease. Lancet. 2:1983;1457-1459.
9. Carvey P.M. Treatment of Movement Disorders in Drug Action in the Central Nervous System. 1998;Oxford University Press, Oxford.
10. Durden, D.A., Paterson, I.A., Davis, B.A., Dyck, L.E., Yu, P.H., Li, X.-M., Boulton, A.A., 1998. Aliphatic propargylamines as cellular rescue agents. USA patent #5,840,979, issued November 24, 1998.
11. Dyck, L.E., Paterson, I.A., Davis, B.A., Durden, D.A., Boulton, A.A., 1998. R-2HMP, its metabolites and related compounds prevent apoptosis in cultured rat cerebellar granule cells. ACNP meeting, Puerto Rico, December 1998, PO 106, 145.
12. Ishitani R., Chuang D.-M. Glyceraldehyde-3-phosphate dehydrogenase antisense oligodeoxynucleotides protect against cytosine arabinoside-induced apoptosis in cultured cerebellar neurons. Proc. Natl. Acad. Sci. USA. 93:1996;9937-9941.
13. Ishitani R., Sunaga K., Hirano A., Saunders P., Katsube N., Chuang D.-M. Evidence that glyceraldehyde-3-phosphate dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture. J. Neurochem. 66:1996;928-935.
14. Ishitani R., Kimura R., Sunaga K., Hirano A., Katsube N., Tanaka M., Chuang D.-M. An antisense oligodeoxynucleotide to glyceraldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. J. Pharmacol. Exp. Ther. 278:1996;447-454.
15. Komives E.A., Ortiz de Montellano P.R. Mechanism of oxidation of bonds by cytochrome P-450. J. Biol. Chem. 262:1987;9793-9802
16. Kragten E., Lalonde I., Zimmerman K., Raggo S., Schindler P., Muller D., van Oostrum J., Waldmeier P., Furst P Glyceraldehyde-3-phosphate dehydrogenase, the putative target of antiapoptotic compounds CGP3466 and R(-) deprenyl. J. Biol. Chem. 273:1998;5821-5828.
17. Lee C.S., Schulzer M., Mak E.X., Snow B.J., Tsui J.K., Calne S., Hammerstad J., Calne D.B. Clinical observations on the rate of progression of idiopathic Parkinsonism. Brain. 117:1994;501-507.
18. Li X.-M., Juorio A.V., Paterson I.A., Zhu M.Y., Boulton A.A. Specific, irreversible, MAO-B inhibitors stimulate gene expression of aromatic L-amino acid decarboxylase in PC12 cells. J. Neurochem. 59:1992;2324-2327.
19. Li X.-M., Qi J., Juorio A.V., Boulton A.A. Reduction in GFAP mRNA abundance induced by (-)deprenyl and other MAO-B inhibitors in C6 glioma cells. J. Neurochem. 61:1993;1573-1576.
20. Li X.-M., Konradi C., Qi J., Juorio A.V., Boulton A.A. (-)Deprenyl down-regulates the low affinity NGF receptor (LNGFR, p75) in PC 12 cells. J. Neurochem. 66(Suppl.):1996;S11A.
21. Li X.-M., Juorio A.V., Qi J., Boulton A.A. L-deprenyl potentiates NGF-induced changes in SOD mRNA in PC12 cells. J. Neurosci. Res. 53:1998;235-238.
22. Li X.-M., Juorio A.V., Qi J., Boulton A.A. L-Deprenyl induces AADC mRNA in rat substantia nigra, an in situ hybridization study. Mol. Chem. Neuropathol. 35:1998;149-155.
23. Meyer-Siegler K., Mauro D.J., Seal G., Wurzer J., deRiel J.K., Sirover M.A. A human nuclear uracil DNA glycosylase is the 37-kDa subunit of GAPDH. Proc. Natl. Acad. Sci. USA. 88:1991;8460-8464.
24. Morgenegg G., Winkler G.C., Hübscher U., Heimann C.W., Mous J., Kuenzle C.C. Glyceraldehyde-3-phosphate dehydrogenase is a nonhistone protein and possible activator of transcription in neurons. J. Neurochem. 47:1986;54-62.
25. Paterson I.A., Tatton W.G. Antiapoptotic actions of monoamine oxidase B inhibitors. Adv. Pharmacol. 42:1998;312-315.
26. Paterson I.A., Barber A.J., Gelowitz D.L., Voll C.L. (-)-Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells. Neurosci. Biobehav. Rev. 21:1997;181-186.
27. Paterson, I.A., Dyck, L.E., Durden, D.A., Davis, B.A., Lui, Y., Boulton, A.A., 1997b. The anti-apoptotic effects of 2HMP is due to a desmethyl metabolite. Soc. Neurosci. Abstr. 23(2) 880.6, p. 2254.
28. Paterson I.A., Zhang D., Warrington R.C., Boulton A.A. R-Deprenyl and R-2-heptyl-N-methylproparglyamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium. J. Neurochem. 70:1998;515-523.
29. Roberts E.S., Hopkins N.E., Zaluzec E.J., Gage D.A., Alworth W.L., Hollenberg P.F. Mechanism-based inactivation of cytochrome P450 2B1 by ethynylphenanthrene. Arch. Biochem. Biophys. 323:1995;295-302.
30. Science, 1998. Special Section on Apoptosis. Science, 281, 1301-1326.
31. Yu P.H. Deamination of aliphatic amines of different chain lengths by rat liver. J. Pharm. Pharmacol. 41:1989;205-208.
32. Yu P.H., Davis B.A., Boulton A.A. Aliphatic propargylamines: potent, selective, irreversible MAO-B inhibition. J. Med. Chem. 35:1992;3705-3713.
33. Yu, P.H., Davis, B.A., Boulton, A.A., 1992b. Aliphatic propargylamines as specific MAO-B inhibitors. USA patent #5,169,868, issued December 8, 1992.
34. Yu P.H., Davis B.A., Boulton A.A. Effect of structural modification of alkyl N-propargylamines on the selective inhibition of MAO-B activity. Biochem. Pharmacol. 46:1993;753-757.
35. Yu, P.H., Davis, B.A., Boulton, A.A., 1995. Aliphatic propargylamines as selective MAO-B inhibitors and neuroprotective agents. USA patent #5,508,311, issued April 16, 1996; Australia patent, issued April 27, 1995; European patent, allowed August 18, 1995; Japanese patent pending; Canadian patent pending.
36. Yu P.H., Zhang X., Zuo D.M., Lai C.T., Tieu K., Davis B.A., Boulton A.A. Aliphatic N-methylpropargylamines as potential neurorescue agents. Restorative Neurol. Neurosci. 12:1998;113-118.
37. Zhang, D., Berry, M.D., Paterson, I.A., Boulton, A.A., 1999. Loss of mitochondrial membrane potential is dependent on the apoptotic programme activated: prevention by R-2HMP. J. Neurosci. Res., in press.